b
r
c
object
evalu
antimycobacteri
activ
melia
azedarach
l
azedarach
lobelia
chinensi
lour
l
chinensi
extract
growth
mycobacterium
tuberculosi
tuberculosi
method
antim
tuberculosi
activ
azedarach
l
chinensi
extract
evalu
use
differ
indic
method
resazurin
microtit
assay
rema
mycobacteria
growth
indic
tube
mgit
system
assay
tuberculosi
incub
variou
concentr
mgml
extract
day
rema
week
mgit
system
assay
result
azedarach
l
chinensi
extract
show
antim
tuberculosi
activ
strongli
inhibit
growth
tuberculosi
concentrationdepend
manner
rema
mgit
system
assay
particularli
methanol
extract
azedarach
nhexan
extract
l
chinensi
consist
exhibit
effect
effect
inhibit
growth
tuberculosi
mgit
system
week
singletreat
indic
higher
antim
tuberculosi
activ
extract
minimum
inhibitori
concentr
measur
mgml
mg
ml
respect
conclus
result
demonstr
azedarach
l
chinensi
extract
uniqu
antim
tuberculosi
activ
also
induc
select
antim
tuberculosi
effect
consist
inhibit
block
growth
tuberculosi
new
pharmacolog
action
therefor
studi
suggest
potenti
effect
candid
agent
nextgener
develop
new
antituberculosi
drug
well
advantag
util
tradit
medicin
plant
one
effect
strategi
tuberculosi
recent
chronic
infecti
diseas
includ
tuberculosi
hepat
filariasi
leishmaniasi
amoebiasi
caus
entamoeba
histolytica
well
acut
infecti
zoonosi
malaria
middl
east
respiratori
syndrom
influenza
ebola
occur
persist
variou
countri
particularli
lessdevelop
countri
global
furthermor
preval
tuberculosi
still
caus
seriou
global
challeng
drugresist
tuberculosi
extens
drugresist
tuberculosi
xdrtb
multidrug
resist
tuberculosi
mdrtb
despit
variou
effort
studi
worldwid
mycobacterium
tuberculosi
tuberculosi
one
major
infecti
factor
caus
highest
mortal
coinfect
hivaid
well
danger
infecti
bacteria
caus
resist
strain
fast
infect
adapt
environment
variat
recent
estim
million
peopl
world
confirm
new
tuberculosi
case
million
hivposit
respons
particularli
tuberculosi
case
coinfect
hivaid
show
highinfect
rate
african
region
compar
countri
tuberculosi
case
occur
asia
african
region
aspect
variou
studi
inhibit
andor
treatment
tuberculosi
carri
antituberculosi
drug
discoverydevelop
field
howev
current
antituberculosi
drug
show
limit
ca
nt
inhibit
increas
tuberculosi
patient
also
caus
variou
side
effect
recent
global
pharmaceut
compani
develop
noveleffect
antituberculosi
drug
test
repurpos
compound
linezolid
chemic
remodel
exist
drug
well
newli
develop
compound
pyridomycin
thiophen
clinic
trial
nevertheless
rapid
emerg
tuberculosi
includ
mdrtb
xdrtb
still
induc
seriou
concern
problem
public
health
field
worldwid
recent
variou
extract
andor
natur
product
deriv
medicin
plant
tradit
orient
medicin
studi
report
discov
novel
antim
tuberculosi
candid
drug
progress
develop
antituberculosi
drug
effectivesaf
nextgener
furthermor
variou
medicin
plant
orient
medicin
util
tradit
resourc
treat
diseas
andor
symptom
diabet
arteriosclerosi
hepat
parasit
cancer
vivo
vitro
reason
variou
studi
develop
effectivesaf
antituberculosi
drug
novel
mechan
action
low
cytotox
least
sideeffect
urgent
need
block
tuberculosi
aspect
studi
carri
evalu
antim
tuberculosi
effect
melia
azedarach
l
azedarach
lobelia
chinensi
lour
l
chinensi
effect
util
medicin
plant
tradit
orient
medicin
identifi
potenti
candid
develop
novel
antitubercular
drug
variou
drug
use
studi
includ
rifampicin
isoniazid
resazurin
powder
dimethylsulfoxid
purchas
sigmaaldrich
chemic
co
ltd
st
loui
mo
usa
system
indic
ml
growth
tube
supplement
kit
purchas
bectondickinson
compani
spark
md
usa
chemic
reagent
purchas
merck
chemic
co
ltd
darmstadt
germani
sigmaaldrich
chemic
co
ltd
st
loui
mo
usa
dri
root
bark
azedarach
dri
root
stem
leav
flower
l
chinensi
provid
orient
medic
center
kyung
hee
univers
seoul
republ
korea
bundang
orient
hospit
dongguk
univers
seoul
republ
korea
studi
azedarach
l
chinensi
extract
accord
solvent
extract
system
follow
five
hundr
gram
powder
azedarach
l
chinensi
independ
extract
l
nhexan
chloroform
ethyl
acet
methanol
distil
water
room
temperatur
h
respect
extract
filter
use
filter
paper
vacuum
pump
evapor
reduc
pressur
use
rotari
evapor
vacuum
c
extract
lyophil
evapor
extract
filter
use
mm
syring
filter
roshi
kaisha
ltd
tokyo
japan
store
c
use
antim
tuberculosi
firstlin
drug
isoniazid
dissolv
steril
distil
water
rifampicin
dissolv
dimethylsulfoxid
concentr
mgml
accord
manufactur
instruct
antim
tuberculosi
firstlin
drug
use
refer
standard
drug
compound
filter
use
mm
membran
syring
filter
roshi
kaisha
ltd
tokyo
japan
use
store
c
deepfreez
use
result
express
mean
sd
three
independ
experi
statist
analysi
data
perform
use
student
ttest
oneway
anova
p
consid
statist
signific
tabl
minim
inhibitori
concentr
mic
valu
extract
viabil
tuberculosi
measur
mgml
tabl
mgml
extract
c
day
sign
indic
antim
tuberculosi
activ
activ
respect
sign
show
inhibitori
rate
extract
growth
tuberculosi
antim
tuberculosi
effect
extract
evalu
use
mgit
system
assay
bacteria
incub
variou
concentr
mgml
extract
antim
tuberculosi
firstlin
drug
mgml
mgit
growth
media
tube
mgit
system
devic
drug
suscept
test
week
growth
unit
markedli
inhibit
concentrationdepend
manner
figur
mgit
system
assay
methanol
extract
azedarach
nhexan
extract
l
chinensi
consist
inhibit
growth
tuberculosi
week
singl
treatment
mgml
mgml
respect
show
effect
select
antim
tuberculosi
activ
well
antim
tuberculosi
action
compar
extract
addit
extract
indic
higher
activ
tuberculosi
tuberculosi
mgit
system
assay
figur
particularli
differ
antim
tuberculosi
activ
obvious
confirm
mgit
system
assay
compar
rema
assay
tabl
result
demonstr
extract
induc
antim
tuberculosi
activ
caus
inactiv
tuberculosi
effect
consist
inhibit
growth
tuberculosi
also
uniqu
antim
tuberculosi
properti
inhibit
block
growth
tuberculosi
concentrationdepend
manner
recent
zoonot
diseas
middl
east
respiratori
syndrom
avian
influenza
ebola
occur
variou
countri
worldwid
divers
infecti
pathway
particularli
asia
middl
east
africa
furthermor
seriou
infecti
pathogen
influenza
tuberculosi
methicillinresist
staphylococcu
aureu
strongli
enhanc
infect
viabil
resist
adapt
drug
well
environment
variat
past
decad
induc
seriou
difficulti
treatment
prevent
diseas
well
develop
effect
drug
particular
diseas
caus
high
risk
symptom
young
children
whose
immun
function
low
elderli
underli
diseas
complic
compar
normal
adult
aspect
tuberculosi
diseas
caus
infect
droplet
caus
high
mortal
preval
rate
compar
contagi
diseas
worldwid
tuberculosi
one
lead
caus
death
among
variou
infecti
diseas
global
particularli
africa
danger
infecti
diseas
caus
complic
bronchiectasi
emphysema
pneumothorax
chronic
symptom
addit
rapid
increas
appear
xdrtbmdrtb
impli
urgent
need
develop
antituberculosi
drug
effectivesaf
nextgener
treat
tuberculosi
recent
despit
variou
effort
discov
develop
new
antituberculosi
drug
develop
effectivesaf
antituberculosi
drug
still
face
direct
indirectdifficulti
includ
cost
time
well
econom
aspect
profit
pharmaceut
furthermor
overus
antibiot
antibacteri
drug
rapidli
increas
preval
incid
rate
resistanttuberculosi
xdrtb
mdrtb
caus
difficulti
treat
tuberculosispati
compar
past
addit
current
antituberculosi
drug
induc
variousseri
side
effect
includ
hepatotox
ototox
nephrotox
aspect
one
feasibl
altern
overcom
limit
drug
side
effect
particularli
includ
rifampicin
isoniazid
ethambutol
moxifloxacin
variou
studi
develop
antituberculosi
drug
report
activ
substanc
deriv
tradit
divers
medicin
plant
biolog
resourc
howev
antituberculosi
agent
effectivesaf
nextgener
util
use
potentialnovel
firstlin
antituberculosi
drug
particularli
extract
natur
product
andor
semisynthet
compound
yet
report
global
pharmaceut
market
perspect
new
pharmacolog
activ
medicin
plant
use
orient
medicin
tradit
medicin
provid
advantag
safeti
efficaci
compar
newli
develop
drug
semisynthet
compound
biomedicin
may
use
util
one
effectivefeas
strategi
develop
antituberculosi
drug
effectivesaf
nextgener
moreov
plant
select
exist
medicin
plant
new
pharmacolog
action
may
increas
potenti
util
usefulfeas
resourc
develop
new
substanc
medic
field
reason
studi
focus
major
key
point
discoveri
new
candid
substanc
one
differ
strategi
develop
antituberculosi
drug
includ
crucial
factor
minim
side
effect
safeti
drug
well
find
novel
pharmacolog
activ
function
medicin
plant
use
korean
tradit
medicin
aspect
azedarach
l
chinensi
medicin
plant
use
biolog
resourc
tradit
orient
medicin
korea
japan
china
well
variou
countri
region
global
includ
variou
bioactiv
substanc
recent
pharmacolog
activ
function
various
report
follow
aqueou
extract
azedarach
induc
effect
wound
heal
activ
growth
keratinocyt
pediculicid
activ
ethanol
extract
azedarach
leav
bark
extract
azedarach
induc
synthas
inhibit
caus
anticanc
activ
antiinflammatori
effect
antidiabet
activ
ethanol
extract
azedarach
antiparasit
effect
hexan
extract
azedarach
gastrointestin
nematod
antibacteri
effect
antifung
activ
extract
azedarach
pathogen
bacteri
fungu
strain
methanol
extract
compound
isol
l
chinensi
induc
antioxid
activ
antiinflammatori
effect
nuclear
factorkb
pathway
antivir
effect
l
chinensi
extract
mous
model
infect
herp
simplex
viru
type
anticanc
effect
compound
isol
l
chinensi
human
lung
cancer
cell
taken
togeth
studi
show
substanti
evid
azedarach
l
chinensi
use
util
therapeut
agent
uniqu
pharmacolog
activ
function
vitro
vivo
howev
despit
pharmacolog
activ
action
identifi
studi
antitubercular
activ
yet
report
vitro
vivo
reason
studi
begun
hypothesi
azedarach
l
chinensi
may
strongli
inhibit
block
effect
modul
growth
tuberculosi
mention
result
studi
show
novel
antitubercular
activ
azedarach
l
chinensi
extract
effect
inhibit
growth
tuberculosi
novel
pharmacolog
activ
properti
particularli
antim
tuberculosi
activ
abil
azedarach
l
chinensi
extract
obvious
demonstr
differ
tuberculosi
susceptibilityind
assay
rema
mgit
system
assay
consist
show
antim
tuberculosi
activ
strongli
inhibit
growth
tuberculosi
week
singl
treatment
mgml
mgml
mgit
system
assay
respect
addit
specif
differ
antim
tuberculosi
activ
obvious
confirm
mgit
system
assay
compar
rema
assay
methanol
extract
azedarach
effect
inhibit
growth
tuberculosi
compar
l
chinensi
extract
result
impli
intracellular
signalingpathway
replic
well
keyprotein
regul
cell
cycl
cytoplasm
acceler
growth
tuberculosi
andor
function
cell
wall
tuberculosi
strongli
inhibit
deactiv
bind
extract
furthermor
extract
show
higher
antim
tuberculosi
activ
tuberculosi
tuberculosi
mgit
system
assay
suggest
result
associ
differ
pathogenesi
virul
two
strain
differ
pathogen
phenotyp
conclus
azedarach
l
chinensi
extract
effect
inhibit
growth
tuberculosi
caus
activ
tuberculosi
weaken
immun
system
novel
pharmacolog
activ
function
antim
tuberculosi
activ
obvious
demonstr
differ
antim
tuberculosi
indic
assay
mgit
system
rema
result
show
effect
use
azedarach
l
chinensi
extract
util
potenti
antim
tuberculosi
agent
consist
inhibit
block
tuberculosi
caus
variou
complic
clinic
field
therefor
studi
provid
signific
evid
potenti
azedarach
l
chinensi
extract
use
util
promis
candid
substanc
develop
novel
antitubercular
drug
effect
nextgener
near
futur
new
pharmacolog
activ
concern
antim
tuberculosi
effect
